Wells Fargo Upgrades Integra Lifesciences to Overweight, Raises Price Target to $49
Wells Fargo Upgrades Integra Lifesciences to Overweight, Raises Price Target to $49
富國銀行將Integra Lifesciences上調至增持，將目標股價提高至49美元
Wells Fargo analyst Larry Biegelsen upgrades Integra Lifesciences (NASDAQ:IART) from Equal-Weight to Overweight and raises the price target from $40 to $49.
富國銀行分析師拉里·比格爾森將Integra Lifesciences（納斯達克股票代碼：IART）從等權重上調至增持，並將目標股價從40美元上調至49美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。